HOME >> MEDICINE >> NEWS
Sex and prenatal hormone exposure affect cognitive performance, Yerkes scientists find

Yerkes researchers are using their findings to better understand sex differences in cognitive performance, which may lead to increased understanding of the difference in neuropsychological disorders men and women experience.

In one of the first research studies to assess sex differences in cognitive performance in nonhuman primates, researchers at the Yerkes National Primate Research Center have found the tendency to use landmarks for navigation is typical only of females.

This finding, which corroborates findings in rodents and humans and is available in the online edition of Hormones and Behavior, suggests there is not just a difference in how well females and males solve spatial problems, but also in which types of cues they use to solve such problems. Researchers are applying this knowledge to gain a better understanding of how the brain develops and functions.

Lead researcher Rebecca Herman, PhD, says the very fact females and males use different strategies suggests there are subtle sex differences in the way the brain develops. As an example of these strategies, Herman said men, when finding a location, generally use north and south as well as distance estimates whereas women prefer physical cues such as street names, signs and buildings. Herman and her collaborator Kim Wallen, PhD, believe a better understanding of how spatial memory develops in healthy women and men may provide insights into abnormal brain development and neuropsychological disorders that show sex differences in prevalence or symptoms, such as attention deficit hyperactivity disorder, Alzheimers disease and autism.

As part of the study, Herman and Wallen compared normal female and male rhesus macaques to those who differed in their prenatal exposure to androgens in order to understand if sex differences were explained by differences in hormone exposure in utero. Some females and males received a drug that blocks the actions of androgens whi
'"/>

Contact: Emily Rios
erios@rmy.emory.edu
404-727-7732
Emory University
12-Apr-2007


Page: 1 2

Related medicine news :

1. New data supports a non-invasive approach to routine prenatal genetic testing
2. Pregnant women in the dark on prenatal screening
3. New prenatal resource center at North General Hospital to open with March of Dimes support
4. Study shows that prenatal exposure to alcohol may cause visual problems in infants
5. 4D ecography for the diagnosis of prenatal cardiopathy
6. Low-carb diets effects linked to rise in newly identified starvation hormone
7. COX inhibitors may weaken protective qualities of estrogen hormone therapy
8. UW study to clarify safety, effectiveness of hormone therapy during menopause
9. Alternative hormone treatment could help fight against breast cancer
10. Reducing cardiovascular disease risk factors when discontinuing hormone replacement therapy
11. Your brain and hormones may conspire to make you fat

Post Your Comments:
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
(Date:1/23/2015)... 23, 2015  HyGreen, Inc., a leader in hand hygiene ... RCA Medical, a subsidiary of Ascendis Health Limited, in ... Each year, hundreds of millions of patients around the ... are transmitted from patient to patient via the unwashed ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
Cached News: